4D Molecular Therapeutics (FDMT) Free Cash Flow (2020 - 2025)
Historic Free Cash Flow for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Q3 2025 value amounting to -$46.4 million.
- 4D Molecular Therapeutics' Free Cash Flow fell 4888.83% to -$46.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$185.1 million, marking a year-over-year decrease of 5849.11%. This contributed to the annual value of -$138.4 million for FY2024, which is 7612.74% down from last year.
- Latest data reveals that 4D Molecular Therapeutics reported Free Cash Flow of -$46.4 million as of Q3 2025, which was down 4888.83% from -$43.4 million recorded in Q2 2025.
- Over the past 5 years, 4D Molecular Therapeutics' Free Cash Flow peaked at -$1.6 million during Q3 2023, and registered a low of -$48.4 million during Q1 2025.
- In the last 5 years, 4D Molecular Therapeutics' Free Cash Flow had a median value of -$26.9 million in 2021 and averaged -$28.0 million.
- In the last 5 years, 4D Molecular Therapeutics' Free Cash Flow surged by 9314.22% in 2023 and then crashed by 187772.84% in 2024.
- 4D Molecular Therapeutics' Free Cash Flow (Quarter) stood at -$26.9 million in 2021, then rose by 13.46% to -$23.3 million in 2022, then dropped by 8.12% to -$25.2 million in 2023, then tumbled by 85.77% to -$46.8 million in 2024, then grew by 0.87% to -$46.4 million in 2025.
- Its Free Cash Flow was -$46.4 million in Q3 2025, compared to -$43.4 million in Q2 2025 and -$48.4 million in Q1 2025.